Date: October 1, 2026
Target Entity: BioForLife Italia S.r.l., Milan, Italy
Type of Deal: Acquisition of 100% share capital
Deal Value: Total consideration of €16.976 million, comprising:
- Base purchase consideration: €15.0 million paid at closing
- Deferred consideration: €1.976 million payable subject to adjustments based on computation of net financial position as on Closing Date (October 1, 2026)
The purchase consideration includes the agreed reference net financial position computed as of June 30, 2026 in terms of the Sale and Purchase Agreement.
Approval Status: Completed with receipt of necessary approvals. Transaction consummated and closed on October 1, 2026.
Transaction Structure: Completed pursuant to Sale and Purchase Agreement dated July 21, 2026, executed between BFL Italy and Alivira Animal Health Limited, Ireland. Representatives of Alivira Animal Health Limited, Ireland have been appointed on the Board of BFL Italy as part of closing.
Corporate Structure: BFL Italy has become a step-down wholly owned subsidiary of Viyash Scientific Limited with effect from October 1, 2026, through Alivira Animal Health Limited, Ireland (which is a step-down wholly owned subsidiary of Viyash).
Regulatory Reference: SEBI Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Previous Disclosures: This announcement is in continuation of earlier disclosures dated June 8, 2026, July 21, 2026, and September 8, 2026.